Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Flame Biosciences | 2020 | Series Unknown | $100.0M | New York |
| BioShin | 2020 | Series A | $60.0M | Shanghai |
| Rain Oncology | 2020 | Series B | $63.0M | Newark |
| Aerovate Therapeutics | 2020 | Series A | $72.6M | Boston |
| Atreca | 2020 | Post Ipo Equity | $125.0M | South San Francisco |
| New Horizon Health | 2020 | Series E | $30.0M | Hangzhou |
| Corvidia | 2020 | Convertible Note | $827K | Waltham |
| Akouos | 2020 | Series B | $105.0M | Boston |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 126 | Flame Biosciences | Series Unknown | $100.0M | New York, United States |
| 127 | BioShin | Series A | $60.0M | Shanghai, China |
| 128 | Rain Oncology | Series B | $63.0M | Newark, United States |
| 129 | Aerovate Therapeutics | Series A | $72.6M | Boston, United States |
| 130 | Atreca | Post Ipo Equity | $125.0M | South San Francisco, United States |
| 131 | New Horizon Health | Series E | $30.0M | Hangzhou, China |
| 132 | Corvidia | Convertible Note | $827K | Waltham, United States |
| 133 | Akouos | Series B | $105.0M | Boston, United States |
| 134 | NuVera Medical | Series B | $15.0M | Los Gatos, United States |
Flame Biosciences is a clinical-stage company focused on therapies for cancer and other inflammatory diseases.
BioShin is a clinical stage biopharmaceutical company.
Rain Oncology is a operator of a clinical stage biotechnology company.
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
New Horizon Health is a bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes.
Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Akouos is a biotechnology company focusing on restoring and preserving hearing.
NuVera Medical is a medical device company
Cormorant Asset Management has invested in 134 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 14 different industry categories.
Among tracked funding rounds, Atreca received $125.0M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $12.5B.
Cormorant Asset Management's average investment size is $116.4M across its portfolio of 134 companies.
Recent Cormorant Asset Management portfolio additions include Flame Biosciences, BioShin, Rain Oncology, Aerovate Therapeutics, Atreca. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors